Neurocrine Biosciences, Inc. (NBIX)

NMS – Real Time Price. Currency in USD

155.80

+5.21 (3.46%)

At close: May 12, 2026, 4:00 PM EDT

156.57

+0.77 (0.49%)

After-hours: May 12, 2026, 7:54 PM EDT

07.05.2026

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

06.05.2026

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance.

06.05.2026

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after starting CRENESSITY CRENESSITY reduces excess androgen production, enabling patients with classic CAH to move toward more physiologic GC dosing while maintaining essential daily cortisol replacement SAN DIEGO, May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Published in The Journal of Clinical Endocrinology & Metabolism, the recommendations address a critical unmet need as real-world use of CRENESSITY expands in both pediatric and adult patients.

06.05.2026

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

05.05.2026

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

05.05.2026

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $0.08 per share a year ago.

05.05.2026

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. "Neurocrine's strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas," said Kyle W.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

05.05.2026

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

04.05.2026

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1 Respondents also reported missing an average of 8 hours of work or school per week due to tardive dyskinesia prior to treatment1 Findings released during Tardive Dyskinesia Awareness Week SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to school, volunteer or actively look for employment. About one in five surveyed working adults with TD reported quitting their job due to TD symptoms prior to treatment.1 Findings are released in recognition of Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of increased awareness, early recognition and appropriate management of TD.

04.05.2026

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'2118 in adult participants. NBIP-'2118 is an investigational corticotropin-releasing factor type 2 receptor (CRF2) peptide agonist and a potential first-in-class therapy for obesity.

Neurocrine Biosciences, Inc. (NBIX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Neurocrine Biosciences, Inc. (NBIX)

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Videos

No Data

Press releases

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Videos

No Data

Press releases

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Search stocks

Neurocrine Biosciences, Inc. (NBIX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Neurocrine Biosciences, Inc. (NBIX)

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Videos

No Data

Press releases

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Videos

No Data

Press releases

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist